Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic Leukemia

Phase 1

Completed

• Conditions: B-cell Acute Lymphoblastic Leukemia

• Registration Number: NCT00289562
• Lead Sponsor: BioCryst Pharmaceuticals

Brief Summary

A Phase I/II, Multi-Center, Open-Label, Repeat-Dose Study of Forodesine Hydrochloride Infusion in Patients with B-cell Acute Lymphoblastic Leukemia with an Option of Extended Use of Forodesine Hydrochloride

Detailed Description

Not available

Study Timeline

• Study Start: 2004-09
• Study First Submitted: 2006-02-08
• Study First Submitted QC: 2006-02-08
• Study First Posted: 2006-02-10
• Primary Completion: 2007-12
• Study Completion: 2007-12
• Status Verified: 2012-01
• Last Update Submitted: 2012-01-19
• Last Update Posted: 2012-01-20

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• Documented B-cell acute lymphoblastic leukemia (B-ALL), which under WHO Guidelines is now referred to as precursor B-lymphoblastic leukemia/lymphoma
• Must have failed at least 1 treatment regimen for B-ALL, which under WHO Guidelines is now referred to as precursor B-lymphoblastic leukemia/lymphoma
• Performance status of ≤2 by Eastern Cooperative Oncology Group (ECOG) criteria
• Any age is allowed
• Life expectancy of at least 3 months
• Adequate liver function (aspartate transaminase [AST] and/or alanine transaminase [ALT] not >3 times upper limits of normal [ULN])
• Adequate kidney function (calculated creatinine clearance >40 mL/min)
• Negative serum or urine pregnancy test within 2 to 7 days prior to the start of study treatment in females of childbearing potential
• Females of childbearing potential and males must be willing and able to use an adequate method of contraception to avoid pregnancy for the duration of the study in such a manner that the risk of pregnancy is minimized. Acceptable contraceptives include intra-uterine devices (IUDs), hormonal contraceptives (oral, depot, patch, or injectable) and double barrier methods such as condoms or diaphragms with spermicidal gel or foam.
• Signed informed consent form (ICF), minor assent form (if applicable), prior to start of any study-specific procedures

Exclusion Criteria

• Active serious infection not controlled by oral or intravenous antibiotics
• Treatment with any investigational antileukemic agent or chemotherapy agent in the last 7 days prior to study entry and lack of full recovery from side effects due to prior therapy independent of when that therapy was given
• Rapidly progressive disease with compromised organ function judged to be life-threatening by the Investigator
• Patients with clinical evidence of active central nervous system (CNS) disease
• Concurrent treatment with other anticancer agents
• Pregnant and/or lactating female
• Patients with known human immunodeficiency virus (HIV) infection HIV testing will be performed at the Screening visit for patients who have not been tested within 6 months of receiving study drug, as well as those patients who have had exposure or have been transfused with blood products that were not appropriately screened.
• Patients with known active hepatitis B and/or hepatitis C infection Hepatitis testing will be performed at the Screening visit for patients who have not been tested within 6 months of receiving study drug, as well as those patients who have had exposure or have been transfused with blood products that were not appropriately screened.
• Hypersensitive or intolerant to any component of the study drug formulation

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP